GlassScriptPhysician profile
Neeraj Vasishtha
NPI 1982689048
$2,074.69
in general payments reported to CMS, 2019-2025
15 companies · $349 in 2025
The $349 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $753 · 2020: $242 · 2021: $91.23 · 2022: $110 · 2023: $330 · 2024: $199 · 2025: $349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $878.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $878.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $751.04 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $211.35 | 2019-2025 | |
| Insmed, INC. | $190.26 | 2019-2025 | Arikayce, Brinsupri |
| Astrazeneca Pharmaceuticals LP | $176.63 | 2019-2024 | Tezspire, Breztri |
| Genzyme Corporation | $173.67 | 2022-2025 | |
| Actelion Pharmaceuticals US, INC. | $120.38 | 2019 | |
| Philips North America LLC | $97.43 | 2019-2024 | (Ak6) Vest Therapy |
| Harmony Biosciences LLC | $82.58 | 2020-2023 | Wakix |
| Novartis Pharmaceuticals Corporation | $77.62 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $69.55 | 2019-2020 | |
| Shire North American Group INC | $43.69 | 2019 | |
| Genentech USA, INC. | $33.00 | 2019-2022 | |
| Electromed, INC. | $18.31 | 2024 | Smartvest |
| Jazz Pharmaceuticals INC. | $14.96 | 2019 | |
| Grifols USA, LLC | $14.22 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neeraj Vasishtha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.